Microfluidic chip for blood testing and testing method therefor
By designing a blood detection microfluidic chip, using microflower geometric cross-design and trace whole blood separation tank, the sensitivity and results of ABO blood type anti-formulation detection and HDN pregnant women's blood type IgG antibody titer detection in the prior art are solved. Stability issues achieve efficient and automated detection results, reducing the influence of human factors and the risk of false negatives.
Patent Information
- Application Number
- PCT/CN2023/098521
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2023-06-06
- Publication Date
- 2024-11-21
AI Technical Summary
The existing ABO blood type anti-formulation detection and HDN pregnant women's blood type IgG antibody titer detection have problems such as insufficient sensitivity, great impact on human factors, many false negative results, and poor reagent stability, especially in microcolumn gels. In the method, the shear stress and bubble influence of the gel card lead to unstable detection results.
A blood detection microfluidic chip is designed, including a trace whole blood separation tank and a reaction test unit, and microfluidic mixing is performed using the geometric cross-design of L-type microfluidic channels and Y-type microfluidic channels to allow repeated centrifugation to enhance the immune agglutination reaction , combined with a trace whole blood separation tank and a plasma extraction groove, the sufficient mixing and reaction between red blood cells and plasma is achieved, avoiding the influence of shear stress, and improving detection stability through anti-human globulin lyophilized bulbs.
Improve the sensitivity of the immune agglutination reaction and the stability of the detection results, reduce the influence of human factors, avoid false negative results, realize miniaturization, fully automated, and high-throughput detection, simplify the operation process, and reduce the reagents cost.
Smart Images

Figure CN2023098521_21112024_PF_FP_ABST
Abstract
Description
A blood detection microfluidic chip and detection method thereof Technical Field
[0001] The present invention relates to blood detection technology, and in particular to a blood detection microfluidic chip and a detection method thereof. Background Art
[0002] The ABO blood typing system is the most immunologically robust of the human blood group systems. Serological tests for ABO blood typing are divided into positive typing and reverse typing. The reverse typing test uses reagent A and B red blood cells to examine serum for anti-A and anti-B antibodies, complementing the positive typing test to improve the accuracy of ABO blood typing. Commonly used methods include the slide method, test tube method, microplate method, and microcolumn gel method. The slide and test tube methods are manual operations with complex procedures, and the accuracy of the results is greatly affected by human factors. They are now gradually being phased out. The microplate method is suitable for analyzing large sample volumes, but requires a large automatic sample pipettor and the results are judged by microscopic observation. Its accuracy is greatly affected by human factors and is rarely used in clinical transfusion departments. The microcolumn gel method is currently a commonly used method, but it also has the following limitations: ① It is insensitive to weak ABO antigen-antibody reactions. The inventors have found that the reason for this insensitivity is that the gel card can only be centrifuged once to see the results and cannot be enhanced by repeated centrifugation. ② When the red blood cell antigen-antibody binding strength is weak, the shear force generated by centrifugation of the gel card exceeds the affinity, and the antibody-dependent red blood cell agglutination is separated, resulting in a false-negative result. ③ During transportation, the reagent gel is easily deformed and bubbles are generated. The temperature also affects the size of the gel molecular sieve, thereby affecting the stability and reliability of the final test results. The above limitations can lead to discrepancies between the positive and negative typing of the microcolumn gel method. In this case, special sample treatment is required to improve the sensitivity of the immune agglutination reaction, or manual methods are used to further clarify the identification.
[0003] Hemolytic disease of the newborn, or HDN, refers to a blood type incompatibility between mother and fetus. The presence of fetal red blood cells in the mother stimulates the production of IgG antibodies, which can cross the placenta and act on the fetal red blood cells, causing varying degrees of hemolysis. Clinically, the incidence of HDN is higher due to ABO and RhD blood type incompatibility. Therefore, dynamic monitoring of maternal IgG antibody titers during pregnancy is crucial for early intervention and treatment.
[0004] Currently, clinical laboratories use the anti-human globulin test for prenatal IgG antibody testing, which is applicable to both the test tube and microcolumn gel methods. The test tube method is manual and complex, and the accuracy of the results is significantly affected by human factors. The microcolumn gel method is currently widely used in clinical laboratories. However, it has some limitations similar to those of the microcolumn gel method for reverse ABO blood typing. These limitations include: ① When the binding strength between red blood cell antigens and antibodies is weak, the shear force generated by centrifugation of the gel card exceeds the affinity, causing antibody-dependent red blood cell agglutination to be dissociated, resulting in false-negative results; ② During transportation, the reagent gel is prone to deformation and bubble formation, and temperature can also affect the size of the gel molecular sieve, thereby affecting the stability and reliability of the final test results.
[0005] Summary of the Invention
[0006] Purpose of the invention: The technical problem to be solved by the present invention is to address the deficiencies of the existing technology and provide a blood testing microfluidic chip suitable for ABO blood type reverse typing detection and HDN pregnant women blood type IgG antibody titer detection, which can improve the sensitivity of immune agglutination reaction detection; at the same time, it uses a small amount of sample, automated detection, and micro-whole blood separation takes into account the hematocrit determination, with a "micro-total analysis" function, providing the conditions for the realization of miniaturized, fully automated, high-throughput supporting analyzers.
[0007] To address the aforementioned technical issues, the first objective of the present invention is to disclose a blood testing microfluidic chip. The chip comprises a chip body, which includes one or more separation and detection units, each of which comprises a micro-whole blood separation tank for receiving and separating a micro-whole blood sample and one or more reaction testing units. When the chip body rotates, red blood cells separated from the micro-whole blood sample settle at one end of the micro-whole blood separation tank, away from the center of the chip body, while plasma separated from the micro-whole blood sample is deposited at the other end of the micro-whole blood separation tank.
[0008] Each reaction test unit includes a first sample loading chamber for receiving plasma from a micro whole blood separation tank, a first L-shaped microfluidic channel, a second sample loading chamber for receiving a corresponding red blood cell reagent, a second L-shaped microfluidic channel, a Y-shaped microfluidic channel, and a reaction detection chamber. The Y-shaped microfluidic channel includes a first sample inlet, a second sample inlet, and an outflow port. The fluids flowing into the first sample inlet and the second sample inlet, respectively, are mixed through the Y-shaped microfluidic channel and discharged from the outflow port. The first L-shaped microfluidic channel connects the first sample loading chamber and the first sample inlet of the Y-shaped microfluidic channel. The second L-shaped microfluidic channel connects the second sample loading chamber and the second sample inlet of the Y-shaped microfluidic channel. The outflow port of the Y-shaped microfluidic channel is connected to the reaction detection chamber.
[0009] Specifically, each of the first L-shaped microfluidic channel and the second L-shaped microfluidic channel is composed of a lower microfluidic channel and a vertical microfluidic channel that are sequentially connected, and the lower microfluidic channel is arranged perpendicular to the vertical microfluidic channel. The inlet of the lower microfluidic channel in the first L-shaped microfluidic channel is connected to the bottom of the first sample loading chamber on the side away from the center of the chip body, and the inlet of the lower microfluidic channel in the second L-shaped microfluidic channel is connected to the bottom of the second sample loading chamber on the side away from the center of the chip body.
[0010] The first inlet, second inlet, and outlet of the Y-shaped microfluidic channel are all located on the upper portion of the chip body. The first inlet of the Y-shaped microfluidic channel is connected to the outlet of the vertical microfluidic channel in the first L-shaped microfluidic channel, and the second inlet of the Y-shaped microfluidic channel is connected to the outlet of the vertical microfluidic channel in the second L-shaped microfluidic channel.
[0011] The Y-shaped microfluidic channel includes two upper-layer inlet microfluidic channels and an upper-layer mixing microfluidic channel. The inlet of one upper-layer inlet microfluidic channel serves as the first sample inlet of the Y-shaped microfluidic channel, while the inlet of the other upper-layer inlet microfluidic channel serves as the second sample inlet of the Y-shaped microfluidic channel. The outlets of the two upper-layer inlet microfluidic channels converge at the inlet of the upper-layer mixing microfluidic channel, and the outlet of the upper-layer mixing microfluidic channel serves as the outlet of the Y-shaped microfluidic channel. Each upper-layer inlet microfluidic channel is arranged perpendicular to the corresponding vertical microfluidic channel.
[0012] In some embodiments, the micro-whole blood separation tank is arranged radially along the chip. The micro-whole blood separation tank includes a plasma extraction groove and a straight tube groove connected to the plasma extraction groove. The straight tube groove is located at one end of the micro-whole blood separation tank away from the center of the chip, while the plasma extraction groove is located at the other end of the micro-whole blood separation tank closer to the center of the chip. Under the action of centrifugal force, the red blood cells obtained after the micro-whole blood sample is separated are all deposited at the end of the straight tube groove away from the center of the chip.
[0013] In some embodiments, the surface of the straight tube groove is provided with a scale mark for judging the hematocrit. The volume of the micro whole blood separation tank is 50-100ul.
[0014] In some embodiments, the number of the reaction test units is six. The chip further includes a plasma dilution pretreatment tank corresponding to each reaction test unit.
[0015] In some embodiments, the reaction detection cavity includes a cylindrical cavity and a tapered cavity with a gradually decreasing diameter, and the large diameter end of the tapered cavity is connected to the bottom end of the cylindrical cavity.
[0016] A second object of the present invention is to provide a method for detecting blood using a microfluidic chip. The method comprises the following steps:
[0017] The first microfluid in the first sample loading chamber flows through the first L-shaped microfluidic channel into the first inlet of the Y-shaped microfluidic channel. The second microfluid in the second sample loading chamber flows through the second L-shaped microfluidic channel into the second inlet of the Y-shaped microfluidic channel. After the first microfluid and the second microfluid are mixed in the Y-shaped microfluidic channel, a first mixture is formed. The first mixture then flows out of the outlet of the Y-shaped microfluidic channel into the reaction detection chamber.
[0018] The microchannels in the microfluidic chip are small in scale, and the fluid flow in the microchannels is laminar, and the corresponding Reynolds number is small, so the mixing between different microfluids mainly relies on diffusion. Therefore, in order to enhance mixing, it is necessary to increase the contact area between the solutes, and the way to increase the contact area can be achieved by stretching the fluid or shearing the fluid. The present application utilizes a pipeline geometric intersection design, by setting an L-shaped microchannel with a pipeline intersection characteristic and setting a vertical microchannel of the L-shaped microchannel and a Y-shaped microchannel to intersect in geometric space. When different microfluids flow through the corresponding L-shaped microchannel and the upper inlet microchannel of the Y-shaped microchannel respectively, the corresponding microfluid first splits into many microclusters, and then promotes the mixing between different microfluid microclusters through the upper mixing microchannel of the Y-type microchannel.
[0019] A third object of the present invention is to provide a method for performing ABO blood type reverse typing using the aforementioned blood testing microfluidic chip. The number of reaction test units is three. The second sample chamber of each reaction test unit receives a red blood cell reagent, a type A red blood cell reagent, and a type O red blood cell reagent, respectively. The detection method comprises the following steps:
[0020] Step 1: The micro whole blood separation tank receives the micro whole blood sample to be tested.
[0021] Step 2: Under the action of centrifugal force, the red blood cells and plasma in the trace whole blood sample to be tested are separated, and the red blood cells obtained after separation are deposited to the end of the straight tube groove away from the center of the chip. The first part of the plasma obtained after separation is accommodated in the plasma extraction groove, and the second part of the plasma obtained after separation is accommodated on the side of the straight tube groove close to the center of the chip.
[0022] Step 3: After centrifugation, the plasma in the plasma extraction groove is aspirated and transferred to the first sample loading chamber of each reaction test unit; the second sample loading chamber of each reaction test unit receives the corresponding red blood cell reagent.
[0023] Step 4: Under the action of centrifugal force, the plasma in the first sample loading chamber flows into the first sample inlet of the Y-shaped microfluidic channel through the first L-shaped microfluidic channel; the red blood cell reagent in the second sample loading chamber flows into the second sample inlet of the Y-shaped microfluidic channel through the second L-shaped microfluidic channel; the plasma and the red blood cell reagent are mixed in the Y-shaped microfluidic channel to form a first mixture, and the first mixture flows out to the reaction detection chamber through the outflow port of the Y-shaped microfluidic channel and fully reacts in the reaction detection chamber.
[0024] Step 5: Let it stand and read the test results.
[0025] If the blood type antibodies in the plasma to be tested undergo an immune agglutination reaction with the blood type antigens in the red blood cell reagent, forming a red blood cell clot, under the action of centrifugal force, the red blood cell clot settles away from the center of the chip; when the chip is stationary, the red blood cell clot remains adhered to the inner side wall of the reaction detection cavity for a certain period of time.
[0026] If the blood type antibodies in the plasma to be tested do not undergo immune agglutination reaction with the blood type antigens in the red blood cell reagent, the red blood cells that have not undergone immune agglutination reaction will settle away from the center of the chip under the action of centrifugal force; when the chip is stationary, the red blood cells that have not undergone immune agglutination reaction will naturally collapse and settle due to the action of gravity.
[0027] The third object of the present invention is to provide a method for detecting the titer of blood type IgG antibodies in HDN pregnant women using the above-mentioned blood detection microfluidic chip. The number of the reaction test units is six. Each reaction test unit is also provided with an independent plasma multiple dilution pretreatment tank for forming a series of multiple dilutions. The second sample loading chamber of each reaction test unit receives the same red blood cell reagent, and the same red blood cell reagent is a type A red blood cell reagent, a type B red blood cell reagent, or an O-type RhD positive red blood cell reagent. The detection method comprises the following steps:
[0028] Step 1: The micro whole blood separation tank receives the micro whole blood sample to be tested.
[0029] Step 2: Under the action of centrifugal force, the red blood cells and plasma in the trace whole blood sample to be tested are separated, and the red blood cells obtained after separation are deposited to the end of the straight tube groove away from the center of the chip. The first part of the plasma obtained after separation is accommodated in the plasma extraction groove, and the second part of the plasma obtained after separation is accommodated on the side of the straight tube groove close to the center of the chip.
[0030] Step 3: After centrifugation, the plasma in the plasma extraction groove is aspirated and transferred to each plasma multiple dilution pretreatment tank in sequence.
[0031] Step 4: pretreat the plasma to be tested in each of the plasma dilution pretreatment tanks with a diluent containing dithiothreitol or dimercaptoethanol, and let it react for 15 to 30 minutes to destroy the activity of IgM antibodies; after the reaction is completed, add the sample diluent to complete the dilution to obtain the diluted plasma.
[0032] Step 5: aspirate the diluted plasma in each plasma dilution pretreatment tank and transfer it to the first sample loading chamber of the corresponding reaction test unit; the second sample loading chamber of each reaction test unit receives the red blood cell reagent.
[0033] Step 6: Under the action of centrifugal force, in each reaction test unit, the doubly diluted plasma in the first sample adding chamber flows into the first sample inlet of the Y-shaped microfluidic channel through the first L-shaped microfluidic channel; the red blood cell reagent in the second sample adding chamber flows into the second sample inlet of the Y-shaped microfluidic channel through the second L-shaped microfluidic channel; the doubly diluted plasma and the red blood cell reagent are mixed in the Y-shaped microfluidic channel to form a first mixture, and the first mixture flows out to the reaction detection chamber through the outflow port of the Y-shaped microfluidic channel and fully reacts in the reaction detection chamber.
[0034] Step 7: Let it stand and read the test results.
[0035] If the blood type antibodies in the plasma to be tested undergo an immune agglutination reaction with the blood type antigens in the red blood cell reagent, forming a red blood cell clot, under the action of centrifugal force, the red blood cell clot settles away from the center of the chip; when the chip is stationary, the red blood cell clot remains adhered to the inner side wall of the reaction detection cavity for a certain period of time.
[0036] If the blood type antibodies in the plasma to be tested do not undergo immune agglutination reaction with the blood type antigens in the red blood cell reagent, the red blood cells that have not undergone immune agglutination reaction will settle away from the center of the chip under the action of centrifugal force; when the chip is stationary, the red blood cells that have not undergone immune agglutination reaction will naturally collapse and settle due to the action of gravity.
[0037] Finally, the reciprocal of the dilution factor at which no immune agglutination reaction occurred in the plasma sample with the highest dilution factor was used as the blood type IgG antibody titer against the specific blood type antigen.
[0038] Preferably, the reaction detection chamber of each reaction test unit is pre-installed with anti-human globulin polyclonal anti-freeze-dried beads. Beneficial effects:
[0039] (1) The present invention provides a blood testing microfluidic chip suitable for ABO blood type reverse typing detection and HDN pregnant women blood type IgG antibody titer detection. The blood testing microfluidic chip of the present application has a "micro-total analysis" function. Unlike the test tube method and micro-gel method, which require multiple steps and multiple vessels to complete, the present application completes the processes of mixing, entering the reaction chamber, centrifugal acceleration reaction, stopping centrifugation and standing, and displaying the reaction results within a single separation and detection unit of a blood testing microfluidic chip, simplifying the operation process and providing the conditions for realizing a miniaturized, fully automated, high-throughput supporting analyzer.
[0040] (2) The present invention can complete the detection with a micro-amount of whole blood sample. The volume of the micro-whole blood separation tank is set to 50-100ul, and the sample injection volume is 40-80ul. This can effectively solve the applicability of those who have difficulty in blood collection, especially newborns, and is also conducive to saving reagent costs.
[0041] (3) The blood detection microfluidic chip of the present invention is a centrifugal microfluidic chip, which is provided with an L-shaped microchannel and a Y-shaped microchannel. Under the action of centrifugal force, the first microfluid in the first sample addition chamber flows through the first L-shaped microchannel into the first inlet of the Y-shaped microchannel. The second microfluid in the second sample addition chamber flows through the second L-shaped microchannel into the second inlet of the Y-shaped microchannel. After the first microfluid and the second microfluid are mixed in the Y-shaped microchannel, a first mixture is formed, and the first mixture flows out to the reaction detection chamber through the outflow port of the Y-shaped microchannel. The present application utilizes a pipeline geometric intersection design, by setting an L-shaped microchannel with a pipeline intersection characteristic and setting the vertical microchannel of the L-shaped microchannel to intersect with the upper inlet microchannel of the Y-shaped microchannel in geometric space. When different microfluids flow through the corresponding L-shaped microchannel and the upper inlet microchannel of the Y-shaped microchannel respectively, the corresponding microfluids are first split into many microclusters, and then the upper mixing microchannel of the Y-shaped microchannel is used to promote the mixing between different microfluid microclusters. This application applies the aforementioned mixing process to the mixing of a red blood cell suspension with other fluids, such as plasma. By utilizing the fluid mechanics of a microfluidic chip, the red blood cell suspension and plasma are fully mixed and reacted to meet the requirements for an immune agglutination reaction. Compared to other mixing methods, such as magnetic stirring, this method offers advantages such as zero carryover, no need for additional materials, no need for structures such as magnetic stirring modules, and a simplified structure for the accompanying analyzer.
[0042] (4) The blood detection microfluidic chip of the present invention allows the immune agglutination reaction of weak antigen-antibody to be enhanced by repeated centrifugation, thereby improving the sensitivity of weak antigen-antibody reaction detection, that is, improving the sensitivity of ABO blood group system reverse typing identification. In the traditional microcolumn gel method, under the action of centrifugal force, the red blood cell agglutination inside the gel card will be subjected to shear stress. When the shear stress is greater than the affinity of the red blood cell antigen-antibody binding, the antibody-dependent red blood cell agglutination will be separated, resulting in a false negative test result. In order to avoid false negative test results, the microcolumn gel method is limited to interpreting the test results after a single centrifugation of the gel card. Although this method ensures the specificity of weak antigen-antibody reaction detection, it reduces the sensitivity of weak antigen-antibody reaction detection. Unlike the traditional microcolumn gel method, if red blood cell antigen-antibody binding occurs in the blood detection microfluidic chip of the present application, during the centrifugation process, the red blood cell agglutination is not affected by the shear stress and is relatively stable, and there is no false negative risk in the microcolumn gel method. Therefore, the blood detection microfluidic chip of the present application allows repeated centrifugation to enhance the immune agglutination reaction of weak antigen-antibody. If an immune agglutination reaction occurs and is sufficient, the red blood cells (RBCs) will aggregate and settle to the inner wall of the reaction chamber under the action of centrifugal force. After standing for a certain period of time, the RBCs will not naturally collapse and settle, remaining vertically attached to the wall of the reaction chamber. A visible button of settled RBCs at the bottom of the reaction chamber indicates the presence of RBC blood type antibodies in the plasma, resulting in a positive result. If no immune agglutination reaction occurs, the centrifugal force is removed and the test is allowed to stand for a period of time. The RBCs that did not undergo an immune agglutination reaction will naturally collapse and settle, gathering along the inverted conical slope at the bottom of the reaction chamber at the center, forming a button of RBCs. This indicates the absence of RBC blood type antibodies in the plasma, resulting in a negative result.
[0043] (5) When the chip of the present invention is used to detect the titer of blood type IgG antibodies in pregnant women with HDN, since there is no shear stress in the microchannel and reaction chamber of the chip during the centrifugation process, the method of detecting the titer of blood type IgG antibodies in pregnant women with HDN using the chip of the present invention avoids the risk of false negative results in the gel microcolumn method.
[0044] (6) When the chip of the present invention is used to detect the titer of IgG antibodies in pregnant women with HDN, anti-human globulin polyclonal antibody freeze-dried beads can be pre-placed in the reaction detection chamber. The stability of freeze-dried bead reagents at room temperature is better than that of liquid reagents. Therefore, the transportation process and temperature have little effect on the stability of chip performance.
[0045] (7) The present invention can use microscopic image photography plus artificial intelligence to judge whether an immune agglutination reaction has occurred, thereby reducing the influence of human factors on the judgment and simplifying the operation steps; at the same time, the image can be permanently stored for easy review, thereby improving the accuracy of the test results.
[0046] (8) The structure of the micro whole blood separation tank of the present application includes a plasma extraction groove and a straight tube groove connected to the plasma extraction groove. By providing the straight tube groove, the tank not only has the function of separating micro whole blood, but also has the function of measuring hematocrit using the capillary method. By providing a scale mark for determining hematocrit on the surface of the straight tube groove, it is convenient to manually read the hematocrit value as a reference for blood transfusion. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more apparent.
[0048] FIG1 is a schematic diagram of the three-dimensional structure of a chip body of a blood testing microfluidic chip for ABO blood type reverse typing detection according to the first embodiment of the present application;
[0049] FIG2 is a top view of the upper layer of a blood testing microfluidic chip for ABO blood type reverse typing detection according to the first embodiment of the present application;
[0050] FIG3 is a top view of the chip body shown in FIG1 ;
[0051] FIG4 is a partial enlarged view of a separation detection unit in the chip body shown in FIG3 ;
[0052] FIG5 is a perspective schematic diagram of a cross-section viewed along line A shown in FIG3 ;
[0053] FIG6 is a schematic diagram of the three-dimensional structure of a chip body of a blood testing microfluidic chip for detecting the titer of blood type IgG antibodies in HDN pregnant women according to the second embodiment of the present application;
[0054] FIG7 is a top view of the upper layer of a blood testing microfluidic chip for detecting the titer of blood type IgG antibodies in HDN pregnant women according to the second embodiment of the present application;
[0055] FIG8 is a top view of the chip body shown in FIG6 ;
[0056] FIG9 is a partially enlarged view of a separation detection unit in the chip body shown in FIG8 .
[0057] The figure marks are as follows: chip body 1; first separation and detection unit 101; second separation and detection unit 102; micro whole blood separation tank 110; plasma extraction groove 111; straight tube groove 112; first sample adding chamber 120; first L-shaped microfluidic channel 130; second sample adding chamber 140; second L-shaped microfluidic channel 150; Y-shaped microfluidic channel 160; first injection port 161; second injection port 162; outflow port 163; reaction detection chamber 170; multiple dilution pretreatment tank 180a, 180b, 180c, 180d, 180e, 180f; chip upper layer 2; micro whole blood separation tank injection hole 201; first sample adding chamber injection hole 202; second sample adding chamber injection hole 203; plasma multiple dilution pretreatment tank injection holes 204a, 204b, 204c, 204d, 204e, 204f. DETAILED DESCRIPTION
[0058] The technical solution of this application is described in detail below with reference to the accompanying drawings.
[0059] Example 1
[0060] This embodiment provides a blood testing microfluidic chip for reverse typing of ABO blood types. The chip comprises a chip body 1 and a chip upper layer 2. FIG1 shows a schematic diagram of the three-dimensional structure of the chip body 1 of this embodiment.
[0061] 2 shows a top view of the chip upper layer 2 of this embodiment. The chip upper layer 2 can be a transparent film that covers the top surface of the chip body 1.
[0062] FIG3 shows a top view of the chip body 1 shown in FIG1 . As shown in FIG3 , the chip body 1 includes six separation and detection units. The six separation and detection units are evenly distributed along the circumference of the rotational axis of the chip body 1. The separation and detection units of this embodiment are equivalent to the first separation and detection unit 101 in FIG3 .
[0063] Figure 4 shows a partial enlarged view of a separation and detection unit in the chip body shown in Figure 3, in which the dotted area represents a separation and detection unit. As shown in Figure 4, each first separation and detection unit 101 includes a micro whole blood separation tank 110 for receiving and separating micro whole blood samples and three reaction test units. The volume of the micro whole blood separation tank 110 is fixed and can be set to 50 to 100ul, and the sample injection volume is 40 to 80ul, which can well solve the applicability problem of people who have difficulty in blood collection, especially newborns. When the chip body 1 rotates at a speed of 2000 to 5000rpm, the red blood cells separated from the micro whole blood sample settle at one end of the micro whole blood separation tank 110 away from the center of the chip body 1, and the plasma separated from the micro whole blood sample is located at the other end of the micro whole blood separation tank 110.
[0064] As shown in Figure 4, each reaction test unit includes a first sample loading chamber 120 for receiving plasma from a micro whole blood separation tank 110, a first L-shaped microfluidic channel 130, a second sample loading chamber 140 for receiving corresponding red blood cell reagents, a second L-shaped microfluidic channel 150, a Y-shaped microfluidic channel 160, and a reaction detection chamber 170. In this embodiment, the red blood cell reagents received by the second sample loading chambers 140 of the three reaction test units are type A red blood cell reagent, type B red blood cell reagent, and type O red blood cell reagent, respectively. Within the same reaction test unit, the first sample loading chamber 120 and the second sample loading chamber 140 are adjacently arranged and are located on the same concentric circle of the rotation center axis of the chip body 1. The first sample loading chamber 120 and the second sample loading chamber 140 are located on the side closer to the center of the chip relative to the reaction detection chamber 170.
[0065] As shown in Figure 4, the Y-shaped microfluidic channel 160 includes a first sample inlet 161, a second sample inlet 162, and an outflow port 163. The fluids flowing into the first sample inlet 161 and the second sample inlet 162 respectively are mixed through the Y-shaped microfluidic channel 160 and then discharged from the outflow port 163. The first L-shaped microfluidic channel 130 connects the first sample loading chamber 120 with the first sample inlet 161 of the Y-shaped microfluidic channel 160. The second L-shaped microfluidic channel 150 connects the second sample loading chamber 140 with the second sample inlet 162 of the Y-shaped microfluidic channel 160. The outflow port 163 of the Y-shaped microfluidic channel 160 is connected to the reaction detection chamber 170.
[0066] During detection, under the action of centrifugal force, the first microfluid in the first sample loading chamber 120 flows through the first L-shaped microfluidic channel 130 into the first sample inlet 161 of the Y-shaped microfluidic channel 160. The second microfluid in the second sample loading chamber 140 flows through the second L-shaped microfluidic channel 150 into the second sample inlet 162 of the Y-shaped microfluidic channel 160. After the first microfluid and the second microfluid are mixed in the Y-shaped microfluidic channel 160, a first mixture is formed, which flows out of the outflow port 163 of the Y-shaped microfluidic channel 160 to the reaction detection chamber 170. The first microfluid and the second microfluid can both be liquids, or at least one of them can be a multiphase mixture. In a specific embodiment, the first microfluid is plasma and the second microfluid is a red blood cell suspension. Under the action of a centrifugal force of 300 to 2000 rpm, the plasma and the red blood cell suspension respectively flow through their corresponding L-shaped microfluidic channels into the Y-shaped microfluidic channel 160. The mixing effect of the Y-shaped microfluidic channel 160 allows the plasma and the red blood cell suspension to mix and react fully. The multiphase mixture formed after the mixing reaction enters and fills the reaction detection chamber 170 .
[0067] Figure 5 shows a three-dimensional schematic diagram of the cross-section in the direction A shown in Figure 3, in which the arrows indicate the direction of fluid flow under the action of centrifugal force. As shown in Figure 5, the first L-shaped microfluidic channel 130 and the second L-shaped microfluidic channel 150 are both composed of a lower microfluidic channel and a vertical microfluidic channel that are connected in sequence, and the lower microfluidic channel is arranged perpendicular to the vertical microfluidic channel. The vertical connection between the lower microfluidic channel and the vertical microfluidic channel forms the pipe intersection characteristic of the L-shaped microfluidic channel. The lower microfluidic channel is provided with a sealing film to prevent the sample from leaking. The inlet of the lower microfluidic channel in the first L-shaped microfluidic channel 130 is connected to the bottom of the side of the first sample loading chamber 120 away from the center position of the chip body 1. The inlet of the lower microfluidic channel in the second L-shaped microfluidic channel 150 is connected to the bottom of the side of the second sample loading chamber 140 away from the center position of the chip body 1.
[0068] The first inlet 161, the second inlet 162, and the outlet 163 of the Y-shaped microfluidic channel 160 are all located at the upper portion of the chip body 1. The first inlet 161 of the Y-shaped microfluidic channel 160 is connected to the outlet of the vertical microfluidic channel in the first L-shaped microfluidic channel 130, and the second inlet 162 of the Y-shaped microfluidic channel 160 is connected to the outlet of the vertical microfluidic channel in the second L-shaped microfluidic channel 150.
[0069] Specifically, as shown in Figure 5, the Y-shaped microfluidic channel 160 includes two upper-layer inlet microfluidic channels and an upper-layer mixing microfluidic channel. The inlet of one of the upper-layer inlet microfluidic channels is the first sample inlet 161 of the Y-shaped microfluidic channel 160, and the inlet of the other upper-layer inlet microfluidic channel is the second sample inlet 162 of the Y-shaped microfluidic channel 160. The outlets of the two upper-layer inlet microfluidic channels meet at the inlet of the upper-layer mixing microfluidic channel. The outlet of the upper-layer mixing microfluidic channel is the outflow outlet 163 of the Y-shaped microfluidic channel 160. The Y-shaped microfluidic channel 160 can be located in a plane perpendicular to the vertical microfluidic channel so that each upper-layer inlet microfluidic channel is perpendicular to the corresponding vertical microfluidic channel.
[0070] This application utilizes a pipeline geometric intersection design by setting up an L-shaped microfluidic channel that has its own pipeline intersection characteristics and setting up a vertical microfluidic channel of the L-shaped microfluidic channel to intersect with the Y-shaped microfluidic channel in geometric space. When different microfluids flow through the corresponding L-shaped microfluidic channel and the upper inlet microfluidic channel of the Y-shaped microfluidic channel in turn, the corresponding microfluids are first split into many microclusters, and then the upper mixing microfluidic channel of the Y-shaped microfluidic channel is used to promote the mixing between different microfluidic microclusters.
[0071] As shown in Figure 5, the micro whole blood separation tank 110 is arranged along the radial direction of the chip. In order to have the function of detecting hematocrit, as shown in Figure 5, the micro whole blood separation tank 110 includes a plasma extraction groove 111 and a straight tube groove 112 connected to the plasma extraction groove 111. The straight tube groove 112 is located at one end of the micro whole blood separation tank 110 away from the center of the chip, and the plasma extraction groove 111 is located at the other end of the micro whole blood separation tank 110 close to the center of the chip. Specifically, the plasma extraction groove 111 in the micro whole blood separation tank 110 is used to receive the micro whole blood sample to be tested. Under the action of centrifugal force, the red blood cells obtained after the separation of the micro whole blood sample are all deposited at the end of the straight tube groove 112 away from the center of the chip, the first part of the plasma is contained in the plasma extraction groove 111, and the second part of the plasma is contained in the end of the straight tube groove 112 close to the center of the chip. In some examples, when the chip body 1 rotates at a speed of 2000-5000 rpm, the trace whole blood in the trace whole blood separation tank 110 is separated.
[0072] In order to facilitate manual interpretation, the surface of the straight tube groove 112 may be provided with a scale mark for interpreting the hematocrit, which is not shown in the figure.
[0073] To improve the sensitivity and accuracy of the reaction detection chamber, as shown in Figure 5, the reaction detection chamber 170 includes a cylindrical cavity and a tapered cavity with a gradually decreasing diameter. The large diameter end of the tapered cavity is connected to the bottom end of the cylindrical cavity.
[0074] As shown in Figure 2, a micro-whole blood separation tank injection hole 201 for adding a micro-whole blood sample is provided at one end of the top of the micro-whole blood separation tank near the center of the chip body 2. A first sample loading chamber injection hole 202 for adding plasma from the micro-whole blood separation tank 110 is provided at one end of the top of the first sample loading chamber 120 near the center of the chip body 2. A second sample loading chamber injection hole 203 for adding a corresponding red blood cell reagent is provided at one end of the top of the second sample loading chamber 140 near the center of the chip body 2. The micro-whole blood separation tank injection hole 201, the first sample loading chamber injection hole 202 and the second sample loading chamber injection hole 203 are all located on the upper layer 2 of the chip.
[0075] Preferably, as shown in Figure 2 , the micro-whole blood separation tank inlet 201, the first sample loading chamber inlet 202, and the second sample loading chamber inlet 203 are each provided with a notch for ventilation. This facilitates the expulsion of air during sample loading, thereby preventing sample from overflowing the wells. The notch can be U-shaped or V-shaped.
[0076] The method for reverse typing ABO blood type using the blood testing microfluidic chip of this embodiment includes the following steps:
[0077] Step 1: The micro whole blood separation tank 110 receives the micro whole blood sample to be tested.
[0078] Step 2: Under the action of centrifugal force, the red blood cells and plasma in the trace whole blood sample to be tested are separated. The separated red blood cells are deposited on the end of the straight tube groove 112 away from the center of the chip. The first part of the plasma is accommodated in the plasma extraction groove 111, and the second part of the plasma is accommodated on the side of the straight tube groove 112 close to the center of the chip.
[0079] Step 3: After centrifugation, the plasma in the plasma extraction groove 111 is aspirated and transferred to the first sample loading chamber 120 of each reaction test unit. The second sample loading chamber 140 of each reaction test unit receives the corresponding red blood cell reagent.
[0080] Step 4: Under the action of centrifugal force, the plasma in the first sample loading chamber 120 flows through the first L-shaped microfluidic channel 130 into the first sample inlet 161 of the Y-shaped microfluidic channel 160. The red blood cell reagent in the second sample loading chamber 140 flows through the second L-shaped microfluidic channel 150 into the second sample inlet 162 of the Y-shaped microfluidic channel 160. Under the action of centrifugal force, the plasma and red blood cell reagent mix in the Y-shaped microfluidic channel 160 to form a first mixture. The first mixture flows out of the outlet 163 of the Y-shaped microfluidic channel 160 into the reaction and detection chamber 170, where it reacts for 1 to 5 minutes. The centrifugal force shortens the distance between red blood cells, promotes the immune agglutination reaction between antibodies and red blood cell antigens, and enhances the intensity of the immune agglutination reaction.
[0081] Step 5: Control the blood detection microfluidic chip to stop rotating, let it stand still, and interpret the detection results.
[0082] In this embodiment, the principle of determining whether an immune agglutination reaction has occurred within each reaction detection chamber 170 is as follows: If the blood type antibodies in the plasma to be tested undergo an immune agglutination reaction with the blood type antigens in the red blood cell reagent, forming a red blood cell clot, under the action of centrifugal force, the red blood cell clot will adhere vertically to the inner wall of the reaction detection chamber 170 due to centrifugal sedimentation. After the blood testing microfluidic chip is controlled to stop rotating, the red blood cell clot will not naturally collapse within a certain period of time when the chip body is in a static state, that is, it will remain adhered to the inner wall of the reaction detection chamber 170 for a certain period of time. The absence of unagglutinated red blood cells at the bottom of the reaction detection chamber 170 indicates a positive result.
[0083] If the blood group antibodies in the plasma to be tested do not undergo an immune agglutination reaction with the blood group antigens in the red blood cell reagent, the red blood cells that have not undergone an immune agglutination reaction will also adhere vertically to the inner wall of the reaction and detection chamber 170 due to centrifugal sedimentation under the action of centrifugal force. However, unlike red blood cell clots, the red blood cells that have not undergone an immune agglutination reaction will naturally collapse and settle due to gravity after being left still for a period of time, forming a large number of unagglutinated red blood cells at the bottom of the reaction and detection chamber 170, indicating a negative result.
[0084] For ABO blood types and Rh weak D antigens, during the static period after a single centrifugation, the amount of red blood cell sedimentation or the sedimentation rate at the bottom of the reaction detection chamber 170 is significantly less than that of the control reaction chamber. The control reaction chamber refers to the reaction detection chamber in the reaction test unit to which the O-type red blood cell reagent is added. In this case, the chip of the present application can directly enhance the immune agglutination reaction by repeating the centrifugation 2–3 times. Compared to the gel method, the chip of the present application can improve the sensitivity of immune agglutination reaction detection through repeated centrifugation, thereby avoiding the discrepancy between positive and negative typing caused by weak antibodies in the traditional microcolumn gel method.
[0085] In this embodiment, the test results can be obtained by visual interpretation or by microscopic photography combined with artificial intelligence analysis. Compared to visual interpretation, microscopic photography combined with artificial intelligence analysis reduces human interference and allows for review because the images are permanently stored, thereby helping to improve the accuracy of the test results.
[0086] In this embodiment, since the bottom of the reaction detection chamber 170 is provided with a conical cavity, the unagglutinated red blood cells gather at the apex of the cone, forming a sedimented red blood cell button. The sedimented red blood cell button provides a clearer, easier to read, more sensitive and accurate interpretation method.
[0087] The results of reverse typing blood typing are shown in Table 1.
[0088] Table 1 Determination of blood type identification results by reverse typing
[0089] Example 2
[0090] This embodiment provides a blood testing microfluidic chip for detecting the titer of IgG antibodies in pregnant women with HDN. The chip comprises a chip body 1 and a chip upper layer 2 covering the top surface of the chip body 1. Figure 6 shows a schematic diagram of the three-dimensional structure of the chip body 1 in the blood testing microfluidic chip of this embodiment. Figure 7 shows a top view of the chip upper layer 2 of this embodiment.
[0091] FIG8 shows a top view of the chip body 1 shown in FIG6 . As shown in FIG8 , the chip body 1 of this embodiment includes three separation and detection units, which are evenly distributed along the circumference of the rotation center axis of the chip body 1. Each separation and detection unit of this embodiment corresponds to the second separation and detection unit 102 in FIG8 .
[0092] Figure 9 shows a partial enlarged view of the second separation and detection unit 102 in the chip body 1 shown in Figure 8, wherein the dotted area represents a separation and detection unit. As shown in Figure 9, unlike Example 1, in each second separation and detection unit 102 of this embodiment, the number of reaction test units is six. In addition, the chip body 1 of this embodiment also includes plasma dilution pretreatment tanks 180a, 180b, 180c, 180d, 180e, and 180f, which are arranged in a one-to-one correspondence with each reaction test unit, for preparing a series of plasma with different dilution factors. This allows users to use the chip of this embodiment without having to prepare separate plasma dilution test tubes, which also helps save consumables. Typically, plasma with dilution factors of 2, 4, 8, 16, 32, and 64 is used for anti-Rh blood type IgG antibody titer determination, and plasma with dilution factors of 64, 128, 256, 512, 1024, and 2048 is used for anti-A and anti-B blood type IgG antibody titer determination.
[0093] In this embodiment, the second sample chamber 140 of each reaction test unit receives the same type of red blood cell reagent, which can be a type A red blood cell reagent, a type B red blood cell reagent, or a type O RhD-positive red blood cell reagent. The type A and type B red blood cell reagents are suitable for detecting the IgG antibody titer of blood types that do not conform to the ABO blood type. The type O RhD-positive red blood cell reagent is suitable for detecting the IgG antibody titer of blood types that do not conform to the Rh type.
[0094] Specifically, the fetus's possible blood type is first predicted based on the blood types of both parents, and then the corresponding red blood cell reagents with known blood types are selected to measure the corresponding antibodies in the maternal blood. For example, if the pregnant woman is type A RhD negative and the father is type B RhD positive, the fetus's blood type could be type A RhD positive, type A RhD negative, type B RhD positive, type B RhD negative, type AB RhD positive, type AB RhD negative, type O RhD positive, or type O RhD negative. In this case, a type B red blood cell reagent and an type O RhD positive red blood cell reagent are required to detect the pregnant woman's anti-B and anti-RhD antibodies, respectively, requiring the use of two separate detection units. If the father is type B RhD negative, the fetus's blood type could be type A RhD negative, type B RhD negative, type AB RhD negative, or type O RhD negative. In this case, only a type B red blood cell reagent is required to detect the pregnant woman's anti-B antibodies, requiring only one separate detection unit.
[0095] As shown in FIG7 , in this embodiment, in addition to the micro whole blood separation tank injection hole 201, the first sample loading chamber injection hole 202, and the second sample loading chamber injection hole 203, the chip upper layer 2 is also provided with six plasma dilution pretreatment tank injection holes 204a, 204b, 204c, 204d, 204e, and 204f. The plasma dilution pretreatment tank injection holes 204a to 204f are sequentially arranged on the top of the plasma dilution pretreatment tanks 180a to 180f. For example, the plasma dilution pretreatment tank injection hole 204a is located at the top of the plasma dilution pretreatment tank 180a, and the plasma dilution pretreatment tank injection hole 204b is located at the top of the plasma dilution pretreatment tank 180b. The rest correspond similarly.
[0096] The method for detecting the titer of blood type IgG antibodies in HDN pregnant women using the blood detection microfluidic chip of this embodiment includes the following steps:
[0097] Step 1: The micro whole blood separation tank 110 receives the micro whole blood sample to be tested.
[0098] Step 2: Under the action of centrifugal force, the red blood cells and plasma in the trace whole blood sample to be tested are separated. The separated red blood cells are deposited on the end of the straight tube groove 112 away from the center of the chip. The first part of the plasma is accommodated in the plasma extraction groove 111, and the second part of the plasma is accommodated on the side of the straight tube groove 112 close to the center of the chip.
[0099] Step 3: After the centrifugation is completed, the plasma in the plasma extraction groove 111 is sucked and transferred to each plasma multiple dilution pretreatment tank in sequence.
[0100] Step 4: Pre-treat the plasma in the plasma dilution pretreatment tank with a diluent containing dithiothreitol (DTT) or dimercaptoethanol (2-ME). Allow to react for 15-30 minutes to inactivate IgM antibodies. After the reaction, add sample diluent to complete the dilution, obtaining diluted plasma. The sample diluent can be PBS (phosphate buffered saline) or normal saline.
[0101] Step 5: aspirate the diluted plasma in each plasma dilution pretreatment tank and transfer it to the first sample loading chamber 120 of the corresponding reaction test unit; the second sample loading chamber 140 of each reaction test unit receives the red blood cell reagent.
[0102] Step 6: Under the action of centrifugal force, in each reaction test unit, the doubly diluted plasma in the first sample loading chamber 120 flows into the first sample inlet 161 of the Y-shaped microfluidic channel 160 through the first L-shaped microfluidic channel 130; the red blood cell reagent in the second sample loading chamber 140 flows into the second sample inlet 162 of the Y-shaped microfluidic channel 160 through the second L-shaped microfluidic channel 150; under the action of centrifugal force, the doubly diluted plasma and the red blood cell reagent are mixed in the Y-shaped microfluidic channel 160 to form a first mixture, which flows out to the reaction detection chamber 170 through the outflow port 163 of the Y-shaped microfluidic channel 160 and is fully reacted in the reaction detection chamber 170 for 1 to 5 minutes.
[0103] Step 7: Control the blood detection microfluidic chip to stop rotating, let it stand still, and interpret the detection results.
[0104] In this embodiment, the principle for determining whether an immune agglutination reaction has occurred in each reaction detection chamber 170 is the same as the determination principle in the first embodiment of this application. If the blood type antibodies in the doubly diluted plasma undergo an immune agglutination reaction with the blood type antigens in the red blood cell reagent, forming a red blood cell clot, under the action of centrifugal force, the red blood cell clot will adhere vertically to the inner wall of the reaction detection chamber 170 due to centrifugal sedimentation. The red blood cell clot will not naturally collapse after being left stationary for a certain period of time, that is, it will remain adhered to the inner wall of the reaction detection chamber 170. The absence of unagglutinated red blood cells at the bottom of the reaction detection chamber 170 indicates a positive result.
[0105] If the blood group antibodies in the diluted plasma do not immunoagglutinate with the blood group antigens in the red blood cell reagent, the non-agglutinated red blood cells will adhere vertically to the inner wall of the reaction and detection chamber 170 due to centrifugal force. However, unlike red blood cell clots, the non-agglutinated red blood cells will naturally collapse and settle due to gravity after standing for a period of time, forming non-agglutinated red blood cells at the bottom of the reaction and detection chamber 170, indicating a negative result. The reciprocal of the dilution factor at which the most diluted plasma sample did not immunoagglutinate is used as the blood group IgG antibody titer for the specific blood group antigen.
[0106] In this embodiment, the reaction chamber 170 of each reaction test unit can be pre-loaded with anti-human globulin polyclonal antibody freeze-dried beads. Freeze-dried beads offer greater stability at room temperature than liquid reagents. The anti-human globulin antibody acts as a secondary antibody, linking specific antibodies that bind to red blood cell antigens and causing red blood cell agglutination.
[0107] In this embodiment, the bottom of the reaction detection chamber 170 can also be provided with a conical cavity. Unagglutinated red blood cells gather at the apex of the cone, forming a sedimented red blood cell button. The sedimented red blood cell button provides a clearer, more sensitive and accurate interpretation method.
[0108] The present invention provides a blood testing microfluidic chip and its concept and method for detection. There are numerous methods and approaches for implementing this technical solution. The above is merely a preferred embodiment of the present invention. It should be noted that those skilled in the art may make various improvements and modifications without departing from the principles of the present invention, and such improvements and modifications are also within the scope of protection of the present invention. Any components not specified in this embodiment may be implemented using existing technologies.
Claims
1. A blood testing microfluidic chip, It is characterized in that The chip comprises a chip body (1), the chip body (1) comprises one or more separation and detection units, each of the separation and detection units comprises a micro whole blood separation tank (110) for receiving and separating a micro whole blood sample and one or more reaction test units; when the chip body (1) rotates, the red blood cells separated from the micro whole blood sample settle at one end of the micro whole blood separation tank (110) away from the center of the chip body (1), and the plasma separated from the micro whole blood sample is located at the other end of the micro whole blood separation tank (110); each of the reaction test units comprises a first sample loading chamber (120) for receiving the plasma from the micro whole blood separation tank (110), a first L-shaped microfluidic channel (130), a second sample loading chamber (140) for receiving a corresponding red blood cell reagent, and a second L-shaped microfluidic channel (131). A flow channel (150), a Y-shaped microfluidic channel (160) and a reaction detection chamber (170); the Y-shaped microfluidic channel (160) comprises a first injection port (161), a second injection port (162) and an outflow port (163); fluids respectively flowing into the first injection port (161) and the second injection port (162) are mixed through the Y-shaped microfluidic channel (160) and then discharged from the outflow port (163); the first L-shaped microfluidic channel (130) connects the first sample addition chamber (120) and the first injection port (161) of the Y-shaped microfluidic channel (160); the second L-shaped microfluidic channel (150) connects the second sample addition chamber (140) and the second injection port (162) of the Y-shaped microfluidic channel (160); the outflow port (163) of the Y-shaped microfluidic channel (160) is connected to the reaction detection chamber (170).
2. A blood detection microfluidic chip according to claim 1, It is characterized in that The first L-shaped microfluidic channel (130) and the second L-shaped microfluidic channel (150) are both composed of a lower microfluidic channel and a vertical microfluidic channel that are connected in sequence, and the lower microfluidic channel is arranged perpendicular to the vertical microfluidic channel; the inlet of the lower microfluidic channel in the first L-shaped microfluidic channel (130) is connected to the bottom of the first sample loading chamber (120) on the side away from the center of the chip body (1); the inlet of the lower microfluidic channel in the second L-shaped microfluidic channel (150) is connected to the bottom of the second sample loading chamber (140) on the side away from the center of the chip body (1); The first sample inlet (161), the second sample inlet (162) and the outlet (163) of the Y-shaped microfluidic channel (160) are all located at the upper part of the chip body (1); the first sample inlet (161) of the Y-shaped microfluidic channel (160) is connected to the outlet of the vertical microfluidic channel in the first L-shaped microfluidic channel (130), and the second sample inlet (162) of the Y-shaped microfluidic channel (160) is connected to the outlet of the vertical microfluidic channel in the second L-shaped microfluidic channel (150); The Y-shaped microfluidic channel (160) comprises two upper inlet microfluidic channels and an upper mixing microfluidic channel; the inlet of one of the upper inlet microfluidic channels is the first sample inlet (161) of the Y-shaped microfluidic channel (160), the inlet of the other upper inlet microfluidic channel is the second sample inlet (162) of the Y-shaped microfluidic channel (160), the outlets of the two upper inlet microfluidic channels meet at the inlet of the upper mixing microfluidic channel, and the outlet of the upper mixing microfluidic channel is the outlet (163) of the Y-shaped microfluidic channel (160); each upper inlet microfluidic channel is arranged perpendicular to the corresponding vertical microfluidic channel.
3. A blood detection microfluidic chip according to claim 2, It is characterized in that The micro whole blood separation groove (110) is arranged along the radial direction of the chip; the micro whole blood separation groove (110) comprises a plasma extraction groove (111) and a straight tube groove (112) connected to the plasma extraction groove (111); the straight tube groove (112) is located at one end of the micro whole blood separation groove (110) away from the center of the chip, and the plasma extraction groove (111) is located at the other end of the micro whole blood separation groove (110) close to the center of the chip; under the action of centrifugal force, the red blood cells obtained after the separation of the micro whole blood sample are all deposited at the end of the straight tube groove (112) away from the center of the chip.
4. A blood detection microfluidic chip according to claim 3, It is characterized in that The surface of the straight tube groove (112) is provided with a scale mark for judging the hematocrit; the volume of the micro whole blood separation tank (110) is 50-100ul.
5. The blood detection microfluidic chip according to claim 1, It is characterized in that The number of the reaction test units is six, and the device also includes plasma multiple dilution pretreatment tanks corresponding to each of the reaction test units.
6. A blood detection microfluidic chip according to any one of claims 1 to 5, It is characterized in that The reaction detection cavity (170) comprises a cylindrical cavity and a conical cavity with a gradually decreasing diameter, and the large diameter end of the conical cavity is connected to the bottom end of the cylindrical cavity.
7. A detection method based on the blood detection microfluidic chip according to claim 2, It is characterized in that The following steps are involved: The first microfluid in the first sample loading chamber (120) flows into the first sample inlet (161) of the Y-shaped microfluidic channel (160) through the first L-shaped microfluidic channel (130); the second microfluid in the second sample loading chamber (140) flows into the second sample inlet (162) of the Y-shaped microfluidic channel (160) through the second L-shaped microfluidic channel (150); After the first microfluid and the second microfluid are mixed in the Y-shaped microfluidic channel (160), a first mixture is formed, and the first mixture flows out to the reaction detection chamber (170) through the outlet (163) of the Y-shaped microfluidic channel (160).
8. A method for performing ABO blood type reverse typing detection using a blood detection microfluidic chip as claimed in claim 3, It is characterized in that The number of the reaction test units is three; the red blood cell reagents received by the second sample loading chamber (140) of each reaction test unit are respectively type A red blood cell reagent, type B red blood cell reagent and type O red blood cell reagent; the detection method comprises the following steps: Step 1: The micro whole blood separation tank (110) receives a micro whole blood sample to be tested; Step 2: under the action of centrifugal force, the red blood cells and plasma in the trace whole blood sample to be tested are separated, and the red blood cells obtained after separation are deposited on the end of the straight tube groove (112) away from the center of the chip, the first part of the plasma obtained after separation is contained in the plasma extraction groove (111), and the second part of the plasma obtained after separation is contained on the side of the straight tube groove (112) close to the center of the chip; Step 3: After the centrifugation is completed, the plasma in the plasma extraction groove (111) is sucked and transferred to the first sample loading chamber (120) of each reaction test unit; the second sample loading chamber (140) of each reaction test unit receives the corresponding red blood cell reagent; Step 4: Under the action of centrifugal force, the plasma in the first sample loading chamber (120) flows into the first sample inlet (161) of the Y-shaped microfluidic channel (160) through the first L-shaped microfluidic channel (130); the red blood cell reagent in the second sample loading chamber (140) flows into the second sample inlet (162) of the Y-shaped microfluidic channel (160) through the second L-shaped microfluidic channel (150); the plasma and the red blood cell reagent are mixed. After the reagents are mixed in the Y-shaped microfluidic channel (160), a first mixture is formed, and the first mixture flows out to the reaction detection chamber (170) through the outflow port (163) of the Y-shaped microfluidic channel (160) and fully reacts in the reaction detection chamber (170); Step 5: Let it stand and read the test results; If the blood type antibodies in the plasma to be tested undergo an immune agglutination reaction with the blood type antigens in the red blood cell reagent, a red blood cell clot is formed; under the action of centrifugal force, the red blood cell clot settles in a direction away from the center of the chip; when the chip is stationary, the red blood cell clot remains adhered to the inner wall of the reaction detection cavity (170) for a certain period of time; if the blood type antibodies in the plasma to be tested do not undergo an immune agglutination reaction with the blood type antigens in the red blood cell reagent, under the action of centrifugal force, the red blood cells that have not undergone an immune agglutination reaction settle in a direction away from the center of the chip; when the chip is stationary, the red blood cells that have not undergone an immune agglutination reaction collapse and settle naturally due to the action of gravity.
9. A method for detecting the titer of blood type IgG antibodies in HDN pregnant women using a blood detection microfluidic chip as described in claim 3, It is characterized in that The number of the reaction test units is six; each reaction test unit is also provided with an independent plasma multiple dilution pretreatment tank correspondingly, for forming a series of multiple dilutions; the second sample loading chamber (140) of each reaction test unit receives the same red blood cell reagent, and the same red blood cell reagent is an A-type red blood cell reagent, a B-type red blood cell reagent or an O-type RhD positive red blood cell reagent; the detection method comprises the following steps: Step 1: the micro whole blood separation tank (110) receives the micro whole blood sample to be tested; Step 2: under the action of centrifugal force, the red blood cells and plasma in the trace whole blood sample to be tested are separated, and the red blood cells obtained after separation are deposited on the end of the straight tube groove (112) away from the center of the chip, the first part of the plasma obtained after separation is contained in the plasma extraction groove (111), and the second part of the plasma obtained after separation is contained on the side of the straight tube groove (112) close to the center of the chip; Step 3: After the centrifugation is completed, the plasma in the plasma extraction groove (111) is sucked and transferred to each of the plasma multiple dilution pretreatment grooves in sequence; Step 4: pretreating the plasma in each of the plasma multiple dilution pretreatment tanks with a diluent containing dithiothreitol (DTT) or dimercaptoethanol (2-ME), and allowing the reaction to stand for 15 to 30 minutes to destroy the activity of IgM antibodies; after the reaction is completed, adding the sample diluent to complete multiple dilution to obtain multiple diluted plasma; Step 5: aspirating the diluted plasma in each of the plasma dilution pretreatment tanks and transferring it to the first sample loading chamber (120) of the corresponding reaction test unit; the second sample loading chamber (140) of each of the reaction test units receives the red blood cell reagent; Step 6: Under the action of centrifugal force, in each of the reaction test units, the double-diluted plasma in the first sample loading chamber (120) flows into the first sample inlet (161) of the Y-shaped microfluidic channel (160) through the first L-shaped microfluidic channel (130); the red blood cell reagent in the second sample loading chamber (140) flows into the second sample inlet (162) of the Y-shaped microfluidic channel (160) through the second L-shaped microfluidic channel (150); the double-diluted plasma and the red blood cell reagent are mixed in the Y-shaped microfluidic channel (160) to form a first A mixture, wherein the first mixture flows out through the outlet (163) of the Y-shaped microfluidic channel (160) to the reaction detection chamber (170) and fully reacts in the reaction detection chamber (170); Step 7: Let it stand and read the test results; If the blood type antibodies in the plasma to be tested react with the blood type antigens in the red blood cell reagent to form a red blood cell clot, the red blood cell clot will settle in a direction away from the center of the chip under the action of centrifugal force; when the chip is stationary, the red blood cell clot will remain adhered to the inner wall of the reaction detection cavity (170) for a certain period of time; If the blood type antibodies in the plasma to be tested do not undergo immune agglutination reaction with the blood type antigens in the red blood cell reagent, under the action of centrifugal force, the red blood cells that have not undergone immune agglutination reaction will settle in the direction away from the center of the chip; when the chip is stationary, the red blood cells that have not undergone immune agglutination reaction will naturally collapse and settle due to gravity; the reciprocal of the dilution multiple at which the plasma sample with the highest dilution multiple does not undergo immune agglutination reaction is taken as the blood type IgG antibody titer against the specific blood type antigen.
10. The method according to claim 9, It is characterized in that Anti-human globulin polyclonal antifreeze-dried beads are preset in the reaction detection chamber (170) of each reaction test unit.
Citation Information
Patent Citations
Blood detection micro-fluidic chip
CN113237799A
Microfluidic blood type detection chip
CN113634295A
Centrifugal micro-fluidic chip, disc feeding device and plasma separating and sampling method
CN115055287A
Cross-matching micro-fluidic chip and detection method thereof
CN116651521A
A micro -fluidic chip for blood group detects
CN206292243U
